Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

View original at globenewswire.com
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cance…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech continues to advance differentiated treatment approaches across lung cancer settings while building clinical evidence to guide further development

    60% confidence

  • Pumitamig plus chemotherapy showed encouraging preliminary antitumor activity and survival outcomes with manageable tolerability profile as first-line therapy in extensive-stage small cell lung cancer

    60% confidence

  • Gotistobart showed a 54% reduction in the risk of death compared with standard of care chemotherapy in squamous NSCLC patients who progressed on prior immunotherapy plus chemotherapy

    60% confidence

  • BioNTech aims to offer patients with lung cancer transformative treatment options that help provide meaningful long-term benefit across all stages of the disease

    60% confidence

  • The data presented at ELCC 2026 further define the potential of BioNTech's late-stage portfolio in lung cancer

    60% confidence

  • BNT326/YL202 showed antitumor activity and favorable safety profile in advanced or metastatic NSCLC patients who progressed after standard of care therapy

    60% confidence

Cited in these Via News reports